Based on ratings from 0 stock analysts, the Horizon Kinetics Medical ETF stock price is expected to decrease by 100% in 12 months. This is calculated by using the average 12-month stock price forecast for Horizon Kinetics Medical ETF. The lowest target is $ and the highest is $. Please note analyst price targets are not guaranteed and could be missed completely.
Horizon Kinetics Medical ETF has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Horizon Kinetics Medical ETF will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of MEDX.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Truist Securities | Hold | Maintains | Jun 22, 2022 | |
HSBC | Hold | Initiates | Nov 23, 2021 | |
RBC Capital | Sector Perform | Maintains | Nov 17, 2021 | |
Jefferies | Hold | Upgrade | Nov 11, 2021 | |
SunTrust Robinson Humphrey | Buy | Maintains | May 21, 2020 | |
SunTrust Robinson Humphrey | Buy | Maintains | May 11, 2020 | |
SunTrust Robinson Humphrey | Buy | Maintains | Apr 13, 2020 | |
CFRA | Buy | Upgrade | Feb 21, 2020 | |
Jefferies | Buy | Upgrade | Jan 21, 2020 | |
Redburn | Neutral | Downgrade | Oct 23, 2019 | |
BTIG | Neutral | Downgrade | Aug 1, 2019 | |
Barclays | Overweight | Upgrade | Jun 20, 2019 | |
UBS | Buy | Upgrade | Oct 26, 2018 | |
DZ Bank | Hold | Downgrade | Oct 18, 2018 | |
HSBC | Buy | Upgrade | Aug 28, 2018 | |
Deutsche Bank | Buy | Upgrade | Apr 24, 2018 | |
Nomura | Buy | Initiates | Mar 17, 2016 | |
UBS | Buy | Upgrade | Jan 5, 2016 | |
SunTrust Robinson Humphrey | Buy | Maintains | Oct 30, 2015 | |
PiperJaffray | Neutral | Maintains | Oct 30, 2015 |
In 2023, MEDX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that MEDX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Eli Lilly raised its 2024 outlook due to strong sales growth of its new obesity drug Zepbound and diabetes treatment Mounjaro.
Why It Matters - Eli Lilly's raised outlook signals strong revenue growth potential, driven by Zepbound and Mounjaro sales, likely boosting investor confidence and stock performance.
Summary - Eli Lilly (LLY) reported strong Q4 2023 earnings, surpassing estimates due to high sales in diabetes and weight-loss treatments.
Why It Matters - Eli Lilly's strong earnings beat signals robust demand for its diabetes and weight-loss drugs, potentially driving stock growth and investor confidence in future performance.
Summary - Eli Lilly (LLY) reported strong Q3 2023 earnings, surpassing estimates for revenue and profit, with continued strong performance from its Mounjaro anti-obesity drug.
Why It Matters - Eli Lilly's strong earnings and Mounjaro's success indicate financial health and growth potential, positively influencing investor sentiment and stock performance.
Summary - Eli Lilly's stock surged significantly after a strong Q2 2023 earnings report and positive outlook, making ETFs with high exposure to the company attractive for investors.
Why It Matters - Eli Lilly's stock surge signals strong financial performance and growth potential, making related ETFs attractive for capitalizing on this momentum.
Summary - The Oakmark Intl Small Cap Fund updated its portfolio for the quarter ending March 31, with the fiscal year concluding in September.
Why It Matters - The Oakmark Intl Small Cap Fund's portfolio updates signal shifts in investment strategy, potentially impacting market trends and investor sentiment in small-cap equities.
Summary - Eli Lilly (LLY) will acquire DICE Therapeutics (DICE) for about $2.4 billion to enhance its immunology pipeline for immune disease treatments.
Why It Matters - Eli Lilly's acquisition of DICE Therapeutics enhances its immunology portfolio, potentially leading to increased market share and revenue from new treatments for immune diseases.